A new meta-analysis shows meaningful differences among FDA-approved antipsychotic adjuncts for MDD, with lumateperone showing the strongest efficacy and aripiprazole the best overall acceptability.

Antipsychotics should not be routinely used to treat primary insomnia in children, adults, or the elderly, according to new recommendations issued by leading Canadian psychiatric organizations. This ...

Get unlimited access to ad-free articles and exclusive content. Kaiser Health News Adriane Fugh-Berman was stunned by the question: Two graduate students who had no symptoms of mental illness wondered ...

Imagine that, after feeling unwell for a while, you visit your GP. "Ah," says the doctor decisively, "what you need is medication X. It's often pretty effective, though there can be side-effects. You ...

Researchers have found in a new study the findings of which reinforce the association between atypical antipsychotic use and ...

When you hear about dementia, the chances are you think about memory problems. But other common symptoms of dementia, including Alzheimer's, can be even more troublesome to patients and their families ...

New research illuminates the benefits and risks of antipsychotic medication in children and its impact on individual well-being, social, educational and/or vocational functioning, and disease burden.

Antipsychotic medication is typically licensed in the UK for people with serious mental health conditions, such as schizophrenia. But in recent years, some antipsychotic drugs have been prescribed ...

For patients in nursing homes, treatment with antipsychotic medicines is pretty much routine. Though the drugs were developed to treat schizophrenia, they're also used to manage the dementia-related ...

An antidepressant appears to work as well as the most commonly prescribed antipsychoticdrug in treating agitation and aggressive behaviour in people with Alzheimer's — minus the severe side-effects, a ...

My first experience with antipsychotic medication was in the early 1960s, shortly after they were introduced. As is usual with new treatments, benefits were appreciated before harms were realized.

In response to a generic question about post-market drug surveillance posed during a February 2007 House Energy and Commerce Committee hearing, Dr. David Graham, then associate director of science and ...